<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="[[Herzinsuffizienz]]  Ursachen für verminderten Cardiac Output  Verminderte Pumpleistung Intrathorakale Druckerhöhung   Einteilung  Akut vs. Chronisch Nach Ejektionsfraktion (normal >55%)  Heart Failure with preserved [[EF]] ≥50% (Heart Failure with mid-range [[EF]]) 40-49% Heart Failure with reduced [[EF]] <40%   Nach Schweregrad ([[NYHA]] I-IV)    Pharmakotherapie der [[Herzinsuffizienz]]  Ziel: Neurohumerale Daueraktivierung unterdrücken ([[Sympathikus]], [[Vasopressin]], [[RAAS]]) Zielgruppe: Nur HFrEF (HFpEF nicht untersucht) Substanzklassen   [[RAAS]]-Inhibitoren"><meta property="og:title" content="Kardiale Pharmakotherapie"><meta property="og:description" content="[[Herzinsuffizienz]]  Ursachen für verminderten Cardiac Output  Verminderte Pumpleistung Intrathorakale Druckerhöhung   Einteilung  Akut vs. Chronisch Nach Ejektionsfraktion (normal >55%)  Heart Failure with preserved [[EF]] ≥50% (Heart Failure with mid-range [[EF]]) 40-49% Heart Failure with reduced [[EF]] <40%   Nach Schweregrad ([[NYHA]] I-IV)    Pharmakotherapie der [[Herzinsuffizienz]]  Ziel: Neurohumerale Daueraktivierung unterdrücken ([[Sympathikus]], [[Vasopressin]], [[RAAS]]) Zielgruppe: Nur HFrEF (HFpEF nicht untersucht) Substanzklassen   [[RAAS]]-Inhibitoren"><meta property="og:type" content="website"><meta property="og:image" content="https://test.vincentweber.neticon.png"><meta property="og:url" content="https://test.vincentweber.net/Kardiale-Pharmakotherapie/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content="Kardiale Pharmakotherapie"><meta name=twitter:description content="[[Herzinsuffizienz]]  Ursachen für verminderten Cardiac Output  Verminderte Pumpleistung Intrathorakale Druckerhöhung   Einteilung  Akut vs. Chronisch Nach Ejektionsfraktion (normal >55%)  Heart Failure with preserved [[EF]] ≥50% (Heart Failure with mid-range [[EF]]) 40-49% Heart Failure with reduced [[EF]] <40%   Nach Schweregrad ([[NYHA]] I-IV)    Pharmakotherapie der [[Herzinsuffizienz]]  Ziel: Neurohumerale Daueraktivierung unterdrücken ([[Sympathikus]], [[Vasopressin]], [[RAAS]]) Zielgruppe: Nur HFrEF (HFpEF nicht untersucht) Substanzklassen   [[RAAS]]-Inhibitoren"><meta name=twitter:image content="https://test.vincentweber.neticon.png"><meta name=twitter:site content="vncntwbr"><title>Kardiale Pharmakotherapie</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://test.vincentweber.net/icon.png><link href=https://test.vincentweber.net/styles.cfbac90e55cfef247c47edcca25506aa.min.css rel=stylesheet><link href=https://test.vincentweber.net/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://test.vincentweber.net/js/darkmode.46cdcb28adbf5d5aad580a2ecf303596.min.js></script>
<script src=https://test.vincentweber.net/js/util.a0ccf91e1937fe761a74da4946452710.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://test.vincentweber.net/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://test.vincentweber.net/js/code-title.4b166cd05b6ea30b114fe3327eb34160.min.js></script>
<script defer src=https://test.vincentweber.net/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://test.vincentweber.net/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://test.vincentweber.net",fetchData=Promise.all([fetch("https://test.vincentweber.net/indices/linkIndex.9719336d754b8c4b5a8bca7a2866a285.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://test.vincentweber.net/indices/contentIndex.74461194be29e1b0438de9e0ad6e2ac7.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://test.vincentweber.net",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://test.vincentweber.net",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/test.vincentweber.net\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=test.vincentweber.net src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://test.vincentweber.net/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://test.vincentweber.net>Vincent's Notes</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Kardiale Pharmakotherapie</h1><p class=meta>Last updated
Feb 11, 2023
<a href=https://github.com/diabolicvincent-git/quartz/tree/hugo/content/Kardiale%20Pharmakotherapie.md rel=noopener>Edit Source</a></p><ul class=tags><li><a href=https://test.vincentweber.net/tags/Modul/m11/>Modul m11</a></li><li><a href=https://test.vincentweber.net/tags/Fach/Kardiologie/>Fach kardiologie</a></li><li><a href=https://test.vincentweber.net/tags/Fach/Pharmakologie/>Fach pharmakologie</a></li></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#herzinsuffizienz>[[Herzinsuffizienz]]</a></li><li><a href=#pharmakotherapie-der-herzinsuffizienz>Pharmakotherapie der [[Herzinsuffizienz]]</a></li></ol></nav></details></aside><a href=#herzinsuffizienz><h2 id=herzinsuffizienz><span class=hanchor arialabel=Anchor># </span><a href=/Herzinsuffizienz rel=noopener class=internal-link data-src=/Herzinsuffizienz>Herzinsuffizienz</a></h2></a><ul><li>Ursachen für verminderten Cardiac Output<ul><li>Verminderte Pumpleistung</li><li>Intrathorakale Druckerhöhung</li></ul></li><li><strong>Einteilung</strong><ul><li>Akut vs. Chronisch</li><li>Nach Ejektionsfraktion (normal >55%)<ul><li>Heart Failure with preserved <a href=/EF rel=noopener class=internal-link data-src=/EF>EF</a> ≥50%</li><li>(Heart Failure with mid-range <a href=/EF rel=noopener class=internal-link data-src=/EF>EF</a>) 40-49%</li><li>Heart Failure with reduced <a href=/EF rel=noopener class=internal-link data-src=/EF>EF</a> &lt;40%</li></ul></li><li>Nach Schweregrad (<a href=/NYHA rel=noopener class=internal-link data-src=/NYHA>NYHA</a> I-IV)</li></ul></li></ul><a href=#pharmakotherapie-der-herzinsuffizienz><h2 id=pharmakotherapie-der-herzinsuffizienz><span class=hanchor arialabel=Anchor># </span>Pharmakotherapie der <a href=/Herzinsuffizienz rel=noopener class=internal-link data-src=/Herzinsuffizienz>Herzinsuffizienz</a></h2></a><ul><li>Ziel: Neurohumerale Daueraktivierung unterdrücken (<a href=/Sympathikus rel=noopener class=internal-link data-src=/Sympathikus>Sympathikus</a>, <a href=/Vasopressin rel=noopener class=internal-link data-src=/Vasopressin>Vasopressin</a>, <a href=/RAAS rel=noopener class=internal-link data-src=/RAAS>RAAS</a>)</li><li>Zielgruppe: Nur <em>HFrEF</em> (HFpEF nicht untersucht)</li><li><strong>Substanzklassen</strong><ul><li><p><a href=/RAAS rel=noopener class=internal-link data-src=/RAAS>RAAS</a>-Inhibitoren</p><ul><li><a href=/ACE-Hemmer rel=noopener class=internal-link data-src=/ACE-Hemmer>ACE-Hemmer</a> ("-pril")<ul><li>Hemmung der Aktivierung von Angiotensin I → Angiotensin II<ul><li>Senkung der <a href=/Nachlast rel=noopener class=internal-link data-src=/Nachlast>Nachlast</a></li><li>Abnahme von Aldosteron → Natriurese, Kaliumretention (NW <a href=/Hyperkali%C3%A4mie rel=noopener class=internal-link data-src=/Hyperkali%C3%A4mie>Hyperkaliämie</a>)</li></ul></li><li>Hemmung des Abbaus von Bradykinin<ul><li><a href=/Vasodilatation rel=noopener class=internal-link data-src=/Vasodilatation>Vasodilatation</a></li><li>Bronchiale Inflammation → NW Reizhusten 15%</li></ul></li><li>Indikationen: HFrEF, art. <a href=/Hypertonie rel=noopener class=internal-link data-src=/Hypertonie>Hypertonie</a>, <a href=/Diabetische-Nephropathie rel=noopener class=internal-link data-src=/Diabetische-Nephropathie>Diabetische Nephropathie</a>, post-<a href=/OMI rel=noopener class=internal-link data-src=/OMI>OMI</a></li><li>NW: <a href=/Hyperkali%C3%A4mie rel=noopener class=internal-link data-src=/Hyperkali%C3%A4mie>Hyperkaliämie</a>, Reizhusten, Angioödem, <a href=/Nierenversagen rel=noopener class=internal-link data-src=/Nierenversagen>Nierenversagen</a>, <a href=/Hypotonie rel=noopener class=internal-link data-src=/Hypotonie>Hypotonie</a></li><li>KI: <a href=/Schwangerschaft rel=noopener class=internal-link data-src=/Schwangerschaft>Schwangerschaft</a>, Stillzeit, Angioödem, Aortenklappenstenose, <a href=/Nierenarterienstenose rel=noopener class=internal-link data-src=/Nierenarterienstenose>Nierenarterienstenose</a> bds., Einzelniere</li></ul></li><li><a href=/AT1-Blocker rel=noopener class=internal-link data-src=/AT1-Blocker>AT1-Blocker</a><ul><li>Unterschied zu ACE-Hemmern: Weniger Reizhusten als NW</li></ul></li></ul></li><li><p>Beta Blocker (→ <a href=/Sympathikus rel=noopener class=internal-link data-src=/Sympathikus>Sympathikus</a>, insb. <a href=/Tachykardie rel=noopener class=internal-link data-src=/Tachykardie>Tachykardie</a> verhindern; &ldquo;-olol&rdquo;)</p><ul><li>Mechanismus<ul><li>Reduzierte symathische Stimulation am <a href=/Herz rel=noopener class=internal-link data-src=/Herz>Herz</a>, negativ <a href=/chronotrop rel=noopener class=internal-link data-src=/chronotrop>chronotrop</a> (führend, <a href=/Tachykardie rel=noopener class=internal-link data-src=/Tachykardie>Tachykardie</a>-Reduktion, Diastolendauer verlängert), negativ <a href=/dromotrop rel=noopener class=internal-link data-src=/dromotrop>dromotrop</a> (NW <a href=/AV-Block rel=noopener class=internal-link data-src=/AV-Block>AV-Block</a>), negativ <a href=/inotrop rel=noopener class=internal-link data-src=/inotrop>inotrop</a></li><li>Verminderung der sympathischen Wirkung auf die <a href=/Niere rel=noopener class=internal-link data-src=/Niere>Niere</a> → Reninausschüttung↓</li></ul></li></ul><p><a class="internal-link broken">Untitled 66.png</a></p><ul><li>Indikationen: HFrEF, <a href=/KHK rel=noopener class=internal-link data-src=/KHK>KHK</a> (<a href=/O2 rel=noopener class=internal-link data-src=/O2>O2</a>-Bedarf reduziert), art. <a href=/Hypertonie rel=noopener class=internal-link data-src=/Hypertonie>Hypertonie</a>, supraventrikuläre <a href=/HRST rel=noopener class=internal-link data-src=/HRST>HRST</a></li><li>NW: <a href=/Bradykardie rel=noopener class=internal-link data-src=/Bradykardie>Bradykardie</a>, <a href=/Hypotonie rel=noopener class=internal-link data-src=/Hypotonie>Hypotonie</a>, SA-/AV-Blockierungen, Bronchokonstriktion (bei β2), periphere Durchblutungsstörungen, <a href=/Hypoglyc%C3%A4mie rel=noopener class=internal-link data-src=/Hypoglyc%C3%A4mie>Hypoglycämie</a>-Neigung (bei β2), Schlaflosigkeit, <a href=/Depression rel=noopener class=internal-link data-src=/Depression>Depression</a>, Sedation, Libidoverlust</li><li>KI: <a href=/Bradykardie rel=noopener class=internal-link data-src=/Bradykardie>Bradykardie</a>, Hypotension, SA-/<a href=/AV-Block rel=noopener class=internal-link data-src=/AV-Block>AV-Block</a>, akute <a href=/Herzinsuffizienz rel=noopener class=internal-link data-src=/Herzinsuffizienz>Herzinsuffizienz</a>, <a href=/Asthma rel=noopener class=internal-link data-src=/Asthma>Asthma</a><ul><li>Relative KI: Spätstadien <a href=/pAVK rel=noopener class=internal-link data-src=/pAVK>pAVK</a>, <a href=/Diabetes-mellitus rel=noopener class=internal-link data-src=/Diabetes-mellitus>Diabetes mellitus</a> mellitus, <a href=/Hypothyreose rel=noopener class=internal-link data-src=/Hypothyreose>Hypothyreose</a></li></ul></li><li>Präparate<ol><li>Generation: Nicht-selektiv (β1=β2), z.B. Propanolol</li><li>Generation: Selektiv (β1>β2), z.B. Metoprolol</li><li>Generation: Nicht-selektiv (β1=β2 + weitere α-Wirkungen), z.B. Bisoprolol</li></ol></li></ul></li><li><p>Aldosteron-(Mineralocorticoid-<a href=/Rezeptor rel=noopener class=internal-link data-src=/Rezeptor>Rezeptor</a>)-Antagonisten</p><ul><li>Mechanismus<ul><li>Binden an cytosolischen Mineralcorticoid-<a href=/Rezeptor rel=noopener class=internal-link data-src=/Rezeptor>Rezeptor</a> → Hemmung der Aldosteron-Wirkung → ENAC-Hemmung (Epithelialer <a href=/Na+ rel=noopener class=internal-link data-src=/Na+>Na+</a> Transporter; durch Aldosteron reguliert) → Hemmung von <a href=/Na+ rel=noopener class=internal-link data-src=/Na+>Na+</a> Resorption und <a href=/K+ rel=noopener class=internal-link data-src=/K+>K+</a> <a href=/Sekretion rel=noopener class=internal-link data-src=/Sekretion>Sekretion</a> (Wirkungseintritt nach 1-3 d)</li></ul></li><li>Indikationen: HFrEF, <a href=/Hyperaldosteronismus rel=noopener class=internal-link data-src=/Hyperaldosteronismus>Hyperaldosteronismus</a> (auch z.B. sekundär durch <a href=/Leberzirrhose rel=noopener class=internal-link data-src=/Leberzirrhose>Leberzirrhose</a>)</li><li>NW: <a href=/Hyperkali%C3%A4mie rel=noopener class=internal-link data-src=/Hyperkali%C3%A4mie>Hyperkaliämie</a>, GI (Übelkeit, Erbrechen, <a href=/Diarrhoe rel=noopener class=internal-link data-src=/Diarrhoe>Diarrhoe</a>), <a href=/endokrin rel=noopener class=internal-link data-src=/endokrin>endokrin</a>e NW (Bindung an Sexualsteroidhormon-<a href=/Rezeptor rel=noopener class=internal-link data-src=/Rezeptor>Rezeptor</a> → anti-<a href=/Androgene rel=noopener class=internal-link data-src=/Androgene>Androgene</a> Effekte, v.a. bei <a href=/Spironolacton rel=noopener class=internal-link data-src=/Spironolacton>Spironolacton</a>, weniger bei Eplerenon)<ul><li>Männer: Gynäkomastie, Impotenz, erhöhte Stimme</li><li>Frauen: Amenorrhoe, Brustspannungen, Hirsutismus</li></ul></li><li>KI: <a href=/Hyperkali%C3%A4mie rel=noopener class=internal-link data-src=/Hyperkali%C3%A4mie>Hyperkaliämie</a>, <a href=/CKD rel=noopener class=internal-link data-src=/CKD>CKD</a> <a href=/GFR rel=noopener class=internal-link data-src=/GFR>GFR</a> &lt;30, <a href=/Dehydratation rel=noopener class=internal-link data-src=/Dehydratation>Dehydratation</a>, <a href=/Hyponatri%C3%A4mie rel=noopener class=internal-link data-src=/Hyponatri%C3%A4mie>Hyponatriämie</a></li></ul></li><li><p><a href=/AT1-Blocker rel=noopener class=internal-link data-src=/AT1-Blocker>AT1-Blocker</a> + Neprilysin-Inhibitoren (ARNI)</p><ul><li>Natriuretische Peptide (NP; ausgeschüttet aus <a href=/Endokard rel=noopener class=internal-link data-src=/Endokard>Endokard</a> bei erhöhter Wandspannung → <a href=/Vasodilatation rel=noopener class=internal-link data-src=/Vasodilatation>Vasodilatation</a>, Diurese gegen <a href=/Hypervol%C3%A4mie rel=noopener class=internal-link data-src=/Hypervol%C3%A4mie>Hypervolämie</a>) normalerweise abgebaut</li><li>Indikation: HFrEF</li><li>NW: s. <a href=/AT1-Blocker rel=noopener class=internal-link data-src=/AT1-Blocker>AT1-Blocker</a></li><li>KI: s. <a href=/AT1-Blocker rel=noopener class=internal-link data-src=/AT1-Blocker>AT1-Blocker</a>, keine Kombination mit <a href=/ACE-Hemmer rel=noopener class=internal-link data-src=/ACE-Hemmer>ACE-Hemmer</a>!</li></ul></li><li><p>If Kanalblocker (→ Funny Channels; z.B. Ivabradin)</p><ul><li>Öffnung der Funny-Channels (langsame diastolische Depolarisation) blockiert → Abflachung des Potentials, isolierte Senkung der <a href=/HF rel=noopener class=internal-link data-src=/HF>HF</a></li><li>KI: <a href=/Bradykardie rel=noopener class=internal-link data-src=/Bradykardie>Bradykardie</a>, <a href=/Schock rel=noopener class=internal-link data-src=/Schock>Schock</a> ?? - <a href=/Digitalis rel=noopener class=internal-link data-src=/Digitalis>Digitalis</a> (Herzgylkoside)</li><li>Hemmung der Na/K-ATPase → Intrazelluläres <a href=/Na+ rel=noopener class=internal-link data-src=/Na+>Na+</a> steigt → Beeinflussung des Na/Ca-Austauschers → positiv <a href=/inotrop rel=noopener class=internal-link data-src=/inotrop>inotrop</a>, positiv <a href=/bathmotrop rel=noopener class=internal-link data-src=/bathmotrop>bathmotrop</a></li><li>Extrakardial: Stimulation zentraler Vaguskerne → negativ <a href=/chronotrop rel=noopener class=internal-link data-src=/chronotrop>chronotrop</a>, negativ <a href=/dromotrop rel=noopener class=internal-link data-src=/dromotrop>dromotrop</a></li><li>Indikation: HFrEF mit <a href=/VHF rel=noopener class=internal-link data-src=/VHF>VHF</a> (negativ <a href=/dromotrop rel=noopener class=internal-link data-src=/dromotrop>dromotrop</a> ausnutzen)<ul><li>Bei Sinusrhythmus Reservepräparat</li></ul></li><li>NW: <a href=/HRST rel=noopener class=internal-link data-src=/HRST>HRST</a> (<a href=/Bradykardie rel=noopener class=internal-link data-src=/Bradykardie>Bradykardie</a>, <a href=/AV-Block rel=noopener class=internal-link data-src=/AV-Block>AV-Block</a>), GI-Beschwerden, Neurotoxische Störungen (u.a. Seh- und Farbstörungen)</li></ul></li><li><p><a href=/Diuretika rel=noopener class=internal-link data-src=/Diuretika>Diuretika</a></p></li></ul></li><li><strong>Therapieregime</strong><ol><li><a href=/ACE-Hemmer rel=noopener class=internal-link data-src=/ACE-Hemmer>ACE-Hemmer</a> + Beta-Blocker</li></ol></li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li>No backlinks found</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://test.vincentweber.net/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Made by Vincent Weber using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, © 2023</p><ul><li><a href=https://test.vincentweber.net>Home</a></li><li><a href=https://twitter.com/vncntwbr>Twitter</a></li></ul></footer></div></div></body></html>